Central trained immunity in the context of bladder cancer immunotherapy
Julia Chronopoulos1, Maria Crespo2, Triantafyllos Chavakis2
1Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany.
Cancer Cell
|July 4, 2025
Abstract:
Two articles in Immunity and Cancer Cell describe that bladder cancer immunotherapy with Bacillus Calmette-Guerin (BCG) alone or in combination with β-glucan, another agonist of trained immunity (TRIM), involves reprogramming of bone marrow (BM) hematopoiesis. These findings provide additional evidence of the therapeutic potential of BM-mediated TRIM against cancer.


